77 related articles for article (PubMed ID: 3186150)
1. Elevated serum iron levels following administration of cisplatinum.
Kletter G; Parks BR; Bhatnagar A; Iyer RV
Oncology; 1988; 45(6):421-3. PubMed ID: 3186150
[TBL] [Abstract][Full Text] [Related]
2. Early and late hyperferremia during cisplatin chemotherapy.
Sartori S; Nielsen I; Masotti M; Malacarne P
J Chemother; 1991 Feb; 3(1):45-50. PubMed ID: 2019863
[TBL] [Abstract][Full Text] [Related]
3. Dose and schedule effects of cisplatin on the related acute iron changes.
Pollera CF; Ameglio F; Nardi M; Marolla P; Carlini P; Frasca AM
Oncology; 1990; 47(2):133-8. PubMed ID: 2314826
[TBL] [Abstract][Full Text] [Related]
4. [Changes in blood iron levels during cisplatin chemotherapy. Preliminary results].
Sartori S; Nielsen I; Malacarne P
Medicina (Firenze); 1990; 10(1):48-9. PubMed ID: 2381283
[TBL] [Abstract][Full Text] [Related]
5. Changes in serum iron levels following very high-dose cisplatin.
Pollera CF; Ameglio F; Reina S; Nardi M; Abbolito MR; Parracino C
Cancer Chemother Pharmacol; 1987; 19(3):257-60. PubMed ID: 3581420
[TBL] [Abstract][Full Text] [Related]
6. The diagnostic accuracy of unbound iron binding capacity (UIBC) as a test for empty iron stores.
Åsberg A; Thorstensen K; Mikkelsen G; Åsberg AE
Scand J Clin Lab Invest; 2013 Apr; 73(3):208-13. PubMed ID: 23391270
[TBL] [Abstract][Full Text] [Related]
7. Interference of deferasirox with assays for serum iron and serum unsaturated iron binding capacity during iron chelating therapy.
Ikuta K; Ito S; Tanaka H; Sasaki K; Torimoto Y; Fujiya M; Kohgo Y
Clin Chim Acta; 2011 Nov; 412(23-24):2261-6. PubMed ID: 21884685
[TBL] [Abstract][Full Text] [Related]
8. Clinical aspects on total iron-binding capacity (TIBC), unsaturated iron-binding capacity (UIBC) and serum iron (SI).
Saito H
Nihon Ketsueki Gakkai Zasshi; 1978 Dec; 41(6):1277-84. PubMed ID: 751408
[No Abstract] [Full Text] [Related]
9. Approaches to the standardization of serum unsaturated iron-binding capacity.
Grahm G; Bates GW
J Lab Clin Med; 1976 Sep; 88(3):477-86. PubMed ID: 956699
[TBL] [Abstract][Full Text] [Related]
10. Lactoferrin levels and unsaturated iron-binding capacity in colostrum of Brazilian women of two socioeconomic levels.
Donangelo CM; Trugo NM; Mesquita VL; Rosa G; Da-Silva VL
Braz J Med Biol Res; 1991; 24(9):889-93. PubMed ID: 1797281
[TBL] [Abstract][Full Text] [Related]
11. [Phase II-III- study of cis-diaminodichloroplatinum (cisplatinum) (author's transl)].
Cortés-Funes H; Moyano A
Med Clin (Barc); 1981 May; 76(9):388-95. PubMed ID: 7017298
[TBL] [Abstract][Full Text] [Related]
12. Effect of serum unbound iron-binding capacity on the tissue distribution of 67Ga in abscess-bearing rabbits.
Scheffel U; Tsan MF
Nuklearmedizin; 1980 Dec; 19(6):274-7. PubMed ID: 7279677
[TBL] [Abstract][Full Text] [Related]
13. The measurement of serum unsaturated iron-binding capacity in the presence of iron-dextran.
Kind CN
Ann Clin Biochem; 1988 May; 25 ( Pt 3)():325-6. PubMed ID: 3400990
[TBL] [Abstract][Full Text] [Related]
14. A fully automated method for determining total serum iron and unsaturated iron-binding capacity using a Technicon AA-II AutoAnalyser system.
Sidloi M; Koch P; Tonks L; Tonks DB
Clin Biochem; 1982 Apr; 15(2):101-5. PubMed ID: 7094284
[TBL] [Abstract][Full Text] [Related]
15. Cisplatinum ototoxicity in children, long-term follow up.
Al-Khatib T; Cohen N; Carret AS; Daniel S
Int J Pediatr Otorhinolaryngol; 2010 Aug; 74(8):913-9. PubMed ID: 20846503
[TBL] [Abstract][Full Text] [Related]
16. Low levels of unsaturated transferrin as a predictor of survival in pneumococcal pneumonia.
Lambert CC; Hunter RL
Ann Clin Lab Sci; 1990; 20(2):140-6. PubMed ID: 2327729
[TBL] [Abstract][Full Text] [Related]
17. [Anti-tumor effects of an angiogenesis inhibitor, TNP-470 (AGM-1470) alone and in combination with cisplatinum, and changes in serum copper levels in liver cancer bearing rats].
Matsuoka S
Hokkaido Igaku Zasshi; 1996 Jan; 71(1):69-80. PubMed ID: 8727376
[TBL] [Abstract][Full Text] [Related]
18. Non-protein bound iron release during chemotherapy in cancer patients.
Weijl NI; Elsendoorn TJ; Moison RM; Lentjes EG; Brand R; Berger HM; Osanto S
Clin Sci (Lond); 2004 May; 106(5):475-84. PubMed ID: 14670072
[TBL] [Abstract][Full Text] [Related]
19. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
[TBL] [Abstract][Full Text] [Related]
20. [Ferrokinetics--pretreatment for intravenous injection of 59-Fe in cases with low unsaturated iron binding capacity (UIBC)--a method for removal of iron from the plasma and complete binding of 59-Fe to autogenous transferrin].
Saito H
Kaku Igaku; 1983 Mar; 20(2):193-8. PubMed ID: 6887639
[No Abstract] [Full Text] [Related]
[Next] [New Search]
